For instance, IgM-2323 is a CD20 × CD3 bispecific IgM antibody developed by IGM Biosciences currently under clinical evaluation in Phase I for the treatment of patients with B cell Non-Hodgkin’s lymphoma (NHL) and other B cell malignancies (NCT04082936). Here, CD40LG is linked to B-cell non-Hodgkin lymphoma.